Good to see new progress in this area:
New research in mice suggests that memory deficits caused by a 22q11.2 microdeletion, which is the single largest genetic risk factor for schizophrenia, can be treated with antagonists of the glycogen synthase kinase 3 β (Gsk3β) protein (Tamura M et al. Neuron. doi:10.1016/j.neuron.2016.01.025 [published online February 18, 2016]).
Gsk3β is involved in energy metabolism, neuronal cell development, and body pattern formation.